Back to Search
Start Over
Gut mycobiome in metabolic diseases: Mechanisms and clinical implication.
- Source :
-
Biomedical journal [Biomed J] 2024 Jun; Vol. 47 (3), pp. 100625. Date of Electronic Publication: 2023 Jun 25. - Publication Year :
- 2024
-
Abstract
- Obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are three common metabolic diseases with high prevalence worldwide. Emerging evidence suggests that gut dysbiosis may influence the development of metabolic diseases, in which gut fungal microbiome (mycobiome) is actively involved. In this review, we summarize the studies exploring the composition changes of gut mycobiome in metabolic diseases and mechanisms by which fungi affect the development of metabolic diseases. The current mycobiome-based therapies, including probiotic fungi, fungal products, anti-fungal agents and fecal microbiota transplantation (FMT), and their implication in treating metabolic diseases are discussed. We highlight the unique role of gut mycobiome in metabolic diseases, providing perspectives for future research on gut mycobiome in metabolic diseases.<br />Competing Interests: Conflicts of interest The authors have no conflicts of interest.<br /> (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2320-2890
- Volume :
- 47
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Biomedical journal
- Publication Type :
- Academic Journal
- Accession number :
- 37364760
- Full Text :
- https://doi.org/10.1016/j.bj.2023.100625